Brief: Recursion And Exscientia Shareholders Approve The Proposed Combination
Nov 13 (Reuters) - Recursion Pharmaceuticals Inc
RXRX.O :
* RECURSION AND EXSCIENTIA SHAREHOLDERS APPROVE THE PROPOSED
COMBINATION
Source text: ID:nGNXbP0Pc
Further company coverage: RXRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Recursion Pharmaceuticals
See all newsBrief: Tempus And Recursion Extend Existing Data License Agreement And Enter New License Agreement For Recursion’S RNA Foundation Model
Brief: Recursion Pharmaceuticals Enters Amendment To Master Agreement With Tempus On Sept 15, 2026 - SEC Filing
Recursion Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Recursion Pharmaceuticals Q2 revenue misses estimates, cuts 2026 expense outlook
Brief: Recursion Pharmaceuticals Q2 Operating Revenue USD 7.303 Million Vs. IBES Estimate USD 11.9 Million